A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

ClinicalTrials.gov ID: NCT07481981

Public ClinicalTrials.gov record NCT07481981. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.

Study identification

NCT ID: NCT07481981
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Insmed Incorporated; Industry
Enrollment: 344 participants

Conditions and interventions

Conditions

Pulmonary Arterial Hypertension

Interventions

Treprostinil Palmitil Inhalation Powder Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 21, 2026 (Actual)
Primary completion: Dec 28, 2028 (Estimated)
Completion: Jan 28, 2029 (Estimated)
Last update posted: Oct 13, 2026

2026 – 2029

United States locations

U.S. sites: 11
U.S. states: 6
U.S. cities: 10

Facility	City	State	ZIP	Site status
USA012	Los Angeles	California	90027	Recruiting
USA008	Santa Barbara	California	93105	Recruiting
USA005	Torrance	California	90502	Recruiting
USA010	Kansas City	Kansas	66160	Recruiting
USA028	Omaha	Nebraska	68198-6450	Recruiting
USA022	New Hyde Park	New York	11042	Recruiting
USA011	New York	New York	10016	Recruiting
USA015	New York	New York	10075	Recruiting
USA013	Rochester	New York	14642	Recruiting
USA006	Philadelphia	Pennsylvania	19140	Recruiting
USA007	Anderson	South Carolina	29621	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07481981, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 13, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07481981 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →